Bukwang Pharmaceutical Co., Ltd. (KRX:003000)
7,280.00
-250.00 (-3.32%)
At close: Apr 8, 2026
Bukwang Pharmaceutical Balance Sheet
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 96,208 | 90,091 | 151,227 | 85,517 | 82,777 |
Short-Term Investments | 120,000 | 40,000 | - | - | 1,500 |
Cash & Short-Term Investments | 216,208 | 130,091 | 151,227 | 85,517 | 84,277 |
Cash Growth | 66.20% | -13.98% | 76.84% | 1.47% | -5.93% |
Accounts Receivable | 27,845 | 23,559 | 35,729 | 87,950 | 90,428 |
Other Receivables | 1,835 | 994.31 | 1,647 | 360.04 | 2,413 |
Receivables | 29,681 | 24,553 | 37,376 | 88,310 | 92,842 |
Inventory | 52,205 | 41,667 | 56,832 | 38,607 | 39,294 |
Prepaid Expenses | 223.5 | 398.29 | 166.97 | 173.46 | 205.7 |
Other Current Assets | 4,860 | 7,030 | 8,576 | 6,134 | 3,476 |
Total Current Assets | 303,177 | 203,739 | 254,179 | 218,741 | 220,095 |
Property, Plant & Equipment | 144,985 | 141,481 | 122,789 | 123,960 | 124,531 |
Long-Term Investments | 15,683 | 16,775 | 31,626 | 35,132 | 36,963 |
Goodwill | - | 406.62 | 878.73 | 834.51 | 828.7 |
Other Intangible Assets | 5,052 | 5,868 | 9,177 | 6,157 | 6,151 |
Long-Term Deferred Tax Assets | - | - | - | - | 3.63 |
Other Long-Term Assets | 7,397 | 4,910 | 10,368 | 16,105 | 8,843 |
Total Assets | 476,295 | 373,180 | 429,017 | 400,929 | 397,417 |
Accounts Payable | 7,297 | 5,062 | 2,368 | 16,530 | 7,421 |
Accrued Expenses | 2,579 | 1,907 | 2,978 | 1,755 | 1,776 |
Current Portion of Long-Term Debt | 79,532 | - | - | - | - |
Current Portion of Leases | 295.3 | 130.19 | 217.6 | 242.91 | 444.17 |
Current Income Taxes Payable | - | - | 357.47 | 4,312 | 3,996 |
Other Current Liabilities | 28,115 | 28,299 | 91,622 | 21,764 | 23,358 |
Total Current Liabilities | 117,818 | 35,398 | 97,544 | 44,603 | 36,995 |
Long-Term Debt | - | 79,024 | 78,525 | - | - |
Long-Term Leases | 513.55 | 269.91 | 644.17 | 687.88 | 1,114 |
Long-Term Deferred Tax Liabilities | 16,615 | 13,917 | 10,068 | 11,011 | 11,217 |
Other Long-Term Liabilities | 416.55 | 425.12 | 7,971 | 72,780 | 68,030 |
Total Liabilities | 135,363 | 129,035 | 194,752 | 129,082 | 117,356 |
Common Stock | 51,507 | 36,402 | 36,402 | 36,402 | 36,402 |
Additional Paid-In Capital | 85,518 | 12,452 | 4,808 | 6,800 | 7,357 |
Retained Earnings | 173,433 | 166,822 | 225,783 | 258,585 | 264,703 |
Treasury Stock | - | - | -50,784 | -50,784 | -50,784 |
Comprehensive Income & Other | 30,142 | 28,000 | 10,103 | 12,215 | 11,930 |
Total Common Equity | 340,600 | 243,676 | 226,311 | 263,217 | 269,608 |
Minority Interest | 332.14 | 469.85 | 7,953 | 8,630 | 10,453 |
Shareholders' Equity | 340,932 | 244,146 | 234,265 | 271,847 | 280,061 |
Total Liabilities & Equity | 476,295 | 373,180 | 429,017 | 400,929 | 397,417 |
Total Debt | 80,341 | 79,424 | 79,387 | 930.79 | 1,558 |
Net Cash (Debt) | 135,867 | 50,667 | 71,840 | 84,586 | 82,719 |
Net Cash Growth | 168.16% | -29.47% | -15.07% | 2.26% | 21.57% |
Net Cash Per Share | 1644.57 | 748.11 | 1049.46 | 1235.65 | 1208.27 |
Filing Date Shares Outstanding | 102.91 | 68.45 | 68.45 | 68.45 | 68.45 |
Total Common Shares Outstanding | 102.91 | 68.45 | 68.45 | 68.45 | 68.45 |
Working Capital | 185,360 | 168,341 | 156,634 | 174,138 | 183,101 |
Book Value Per Share | 3309.59 | 3559.67 | 3306.00 | 3845.13 | 3938.48 |
Tangible Book Value | 335,548 | 237,401 | 216,255 | 256,226 | 262,628 |
Tangible Book Value Per Share | 3260.49 | 3468.00 | 3159.10 | 3743.01 | 3836.52 |
Land | 112,939 | 113,314 | 92,875 | 92,875 | 92,875 |
Buildings | 52,274 | 51,499 | 51,450 | 50,602 | 50,602 |
Machinery | 47,785 | 49,276 | 48,406 | 48,080 | 46,343 |
Construction In Progress | 527.8 | 311.17 | - | 76.21 | - |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.